Drug Safety Evaluation 4th Edition Shayne Cox Gad – Ebook Instant Download/Delivery ISBN(s): 9781119755852,1119755859,9781119755876
Product details:
- ISBN 10: 1119755875
- ISBN 13: 9781119755876
- Author: Shayne Cox Gad
This fourth edition of Drug Safety Evaluation maintains the central objective of presenting an all-inclusive practical guide for those who are responsible for ensuring the safety of drugs and biologics to patients, healthcare providers, those involved in the manufacture of medicinal products, and all those who need to understand how the safety of these products is evaluated and shepherding valuable candidates to market.
Individual chapters address specific approaches to evaluation hazards, including problems that are encountered and their solutions. Also covered are the scientific and philosophical bases for evaluation of specific concerns (e.g., carcinogenicity, development toxicity, etc.) to provide both understanding and guidance for approaching the new problems that have come to face both our society and the new challenges they brought.
The many changes in regulatory requirements, pharmaceutical development, technology, and the effects of Covid on our society and science have required both extensive revision to every chapter and the addition of four new chapters.
Table contents:
1 The Drug Development Process and The Global Pharmaceutical Marketplace
2 Regulation of Human Pharmaceutical Safety: Routes To Human Use and Market
3 Data Mining: Sources of Information For Consideration In Study And Program Design and In Safety Evaluation
4 Electronic Records, Reporting, and Submission: eCTD and Send
5 Screens in Safety and Hazard Assessment
6 Formulations, Routes, and Dosage Regimens
7 Mechanisms And End Points Of Drug Toxicity
8 Pilot Toxicity Testing In Drug Safety Evaluation: MTD and DRF
9 Repeat-Dose Toxicity Studies
10 Genotoxicity
11 QSAR Tools For Drug Safety
12 Toxicogenomics
13 Immunotoxicology In Drug Development
14 Nonrodent Animal Studies
15 Developmental And Reproductive Toxicity Testing
16 Carcinogenicity Studies
17 Histopathology and Clinical Pathology In Nonclinical Pharmaceutical Safety Assessment
18 Irritation And Local Tissue Tolerance In Pharmaceutical Safety Assessment
19 Pharmacokinetics And Toxicokinetics In Drug Safety Evaluation
20 Safety Pharmacology
21 Special Concerns For The Preclinical Evaluation Of Biotechnology Products
22 Safety Assessment of Inhalant Drugs And Dermal Route Drugs
23 Special Case Products: Imaging Agents
24 Special Case Products: Drugs For Treatment Of Cancer
25 Pediatric Product Safety Assessment (2006 Guidance, Including Juvenile And Pediatric Toxicology)
26 Use Of Imaging, Imaging Agents, And Radiopharmaceuticals In Nonclinical Toxicology
27 Occupational Toxicology In The Pharmaceutical Industry
28 Strategy and Phasing For Nonclinical Drug Safety EvaluationIn The Discovery and Development of Pharmaceuticals
29 The Application of In Vitro Techniques In Drug Safety Assessment
30 Evaluation Of Human Tolerance And Safety In Clinical Trials: Phase I And Beyond
31 Postmarketing Safety Evaluation: Monitoring, Assessing, And Reporting of Adverse Drug Responses (ADRs)
32 Statistics In Pharmaceutical Safety Assessment
33 Combination Products: Drugs and Devices
34 Qualification Of Impurities, Degradants, Residual Solvents, Metals, and Leachables in Pharmaceuticals
35 Tissue, Cell, and Gene Therapy
36 Adverse Outcome Pathways in Drug Safety Assessment
People also search:
center for drug safety evaluation and research
cardiac drug safety evaluation
genomics in preclinical drug safety evaluation
drug safety evaluation in special population slideshare
drug safety evaluation in pediatrics slideshare